Assays have been developed for three phenotypes of particular clinical significance: NPM1, Core Bind Factor (CBF)-AML (referring to the fusions gene RUNX1::RUNX1T1 and CBFB::MYH11) and Acute Promyelocytic Leukemia (APL) (referring to the fusion gene PML::RARA) [10]. Here, CEBPZ is linked to acute promyelocytic leukemia.